Since 2014, David is an European Molecular Biology Laboratory (EMBL) Australia Group Leader in the Infection and Immunity Theme at the South Australian Health and Medical Research Institute (SAHMRI). He also holds a joint faculty appointment as Associate Professor at the College of Medicine & Public Health, Flinders University. David heads a multi-disciplinary group that is equally divided between bioinformatics and experimental systems biology. On the wet-lab side, his group employs in vitro and in vivo experimental and clincial models coupled with systems biology approaches to investigate the interplay between the microbiome, vaccines and the immune system. On the bioinformatics side, his group leads the development of InnateDB.com, an internationally recognised systems biology platform for innate immunity networks and he also leads the computational biology aspects of ‚¬12 million European Commission funded project called PRIMES, which is investigating how to model and subsequently therapeutically target protein interaction networks in cancer.

His Group is currently supported by; EMBL Australia; The NHMRC; Cancer Australia and The Garnett Passe and Rodney Williams Memorial Foundation. He has published ~70 papers in journals including Cell Host & Microbe, Cell Systems, Bioinformatics, Molecular Systems Biology, and Science and his publications have received more than 5000 citations. He has given invited talks on 6 continents.

David heads a multi-disciplinary group that is equally divided between bioinformatics and experimental systems biology. On the wet-lab side, his group employs in vitro and in vivo experimental and clincial models coupled with systems biology approaches to investigate the interplay between the microbiome, vaccines and the immune system. On the bioinformatics side, his group leads the development of InnateDB.com, an internationally recognised systems biology platform for innate immunity networks and he also leads the computational biology aspects of ‚¬12 million European Commission funded project called PRIMES, which is investigating how to model and subsequently therapeutically target protein interaction networks in cancer.